Is Teva-Amneal Inhaler Case A Double-Edged Sword For The Generics Industry?
Teva Filed For En Banc Hearing Following The Appellate Court Decision
The Teva v. Amneal battle over inhaler patents in the FDA’s Orange Book has become a noteworthy case that will impact both branded and generic drug companies. Yet, the clarity over patent listings might be overshadowed by possible future litigations, discussed law firm Polsinelli’s chair Chad Landmon with Generics Bulletin.
